therapeutic_4

Fab, F(ab’)2, and Fc fragments expand antibody applications. Biointron explains their structures and how they advance diagnostics, imaging, and therapeutic innovation.

The development and approval of novel antibody drugs represent a significant segment of pharmaceutical innovation, addressing a wide range of diseases from cancer to autoimmune disorders. Since the first monoclonal antibody (mAb) drug was approved in 1986, there has been explosive growth in this area. By 2021, the US FDA had approved its 100th mAb product, with mAbs now accounting for nearly a fifth of the agency’s new drug approvals each year.

Bispecific antibodies are transforming medicine. Biointron highlights their design, therapeutic applications, and development pathways for next-generation therapies.

This week, exciting news came out that Eledon Pharmaceuticals’ tegoprubart was successfully used to aid the first-ever transplant of a genetically-edited pig kidney into a 62-year-old man with end-stage kidney disease. Tegoprubart is an investigational anti-CD40L antibody that has a high affinity for CD40 ligand. CD40L signaling plays an important role in adaptive and innate immune cell activation and function, and is therefore a target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.

CROs speed up drug development. Biointron demonstrates how its expertise in antibody discovery, expression, and characterization helps partners achieve faster results.

Single B cell technology accelerates antibody discovery. Biointron demonstrates how this approach delivers potent candidates faster and with greater precision.

Image credit: DOI: 10.3390/cancers16040800 In recent decades, the landscape of therapeutic antibodies has undergone a rapid evolution, catalyzing breakthroughs in modern medicine. These antibodies, characterized by their precise targeting and minimal side effects

The nucleocapsid of a virus, which consists of the capsid enclosing the viral nucleic acid, can be a target for antibody therapies. When a virus infects a host, its nucleocapsid becomes exposed to the immune system, triggering the production of antibodies specific to proteins present on the nucleocapsid's surface, preventing the virus from entering host cells, disrupting its replication cycle, or marking it for destruction by other components of the immune system.

In the realm of combating bacterial infections and antimicrobial resistance, antibodies are beginning to stand out as a therapy with innovative strategies and engineering methods continually being published. This month’s trend will focus on the developments in ‘antibiotic antibodies’, antibody-antibiotic conjugates, and antibody antimicrobials, which are particularly important for immunocompromised patients.

Agonist antibodies activate receptors to modulate biology. Biointron explores their mechanisms, therapeutic promise, and applications in immune regulation and oncology.

Toxins are substances produced by living organisms, such as bacteria, fungi, plants, and animals, that are harmful to other organisms. Antibodies play a crucial role in immune responses for the body's defense against toxin intoxication, in addition to being invaluable tools for both diagnostic and therapeutic applications.

Recombinant antibody production ensures reproducibility and accuracy. Biointron provides reliable expression and purification to create research tools that advance discovery.

CHO cell line development is central to therapeutic antibody production. Biointron optimizes expression systems to deliver scalable, reliable, and high-yield solutions.

Therapeutic antibody discovery begins with screening. Biointron applies ELISA, SPR, and AI-driven tools to identify high-affinity antibodies with precision and speed.

Single-chain variable fragments (scFvs) combine small size with strong binding. Biointron highlights their history, uses in diagnostics and therapy, and production expertise.